Trazodone Cost in Minnesota (2026): Prices, Insurance, and Savings

Trazodone hydrochloride (brand names historically Desyrel and Oleptro, now sold almost entirely as generic tablets) is a serotonin antagonist and reuptake inhibitor (SARI) that the FDA approved in 1981 for major depressive disorder. It is not a controlled substance under the DEA schedule system, and it has been off-patent for decades, which is why generic versions from multiple manufacturers dominate the market.

The useful question for a Minnesota reader is not "what does trazodone cost" but what determines the cost for a given prescription: because trazodone is a long-off-patent generic, the cash price is usually low almost everywhere, and the bigger cost variable is whether a specific insurance plan or Medicaid managed care organization places it on a preferred tier, requires prior authorization, or covers an off-label indication like insomnia at all.

Direct answer: Generic trazodone is one of the lowest-cost oral antidepressants and insomnia medications on the U.S. market because it has been available from multiple generic manufacturers since the mid-1980s; most commercial and Medicare Part D plans place it on the lowest generic cost-sharing tier, and Medicaid programs generally cover it, though state-specific copay amounts, prior authorization rules, and current cash prices at individual Minnesota pharmacies change over time and require direct verification rather than a single quoted number.

Cash price: what is established and what is not

Independent, generic, off-patent oral medications like trazodone typically retail in the range of a few dollars to around fifteen dollars for a 30-day supply at U.S. chain and discount pharmacies, and discount cards (GoodRx, SingleCare, RxSaver) frequently list further reductions. That general pattern is well established for the category of long-generic oral drugs. What is not established from the sources available for this article is a specific, current dollar figure for Minnesota pharmacies in 2026. Cash prices change by pharmacy, strength, and week, and the earlier version of this page stated a precise "$10 average" and a "$40 list price" without a Minnesota-specific or dated source. Readers should treat any single cash-price number, including ones on this page, as a starting estimate to confirm with a pharmacy or a discount-card lookup at the time of fill, not as a fixed 2026 fact.

Trazodone's cost sits well below branded orexin-receptor antagonists used for insomnia, such as suvorexant (Belsomra) and lemborexant (Dayvigo), which remain on-patent brand products FDA Belsomra approval record. That comparison is directional and reliable (generic vs. brand-name patent-protected drug); the exact dollar gap between them is volatile and should be checked against current pharmacy or plan pricing rather than quoted as fixed.

Minnesota Medicaid and Medical Assistance

Medicaid programs across the country, including state-run Medical Assistance programs, are required to cover most FDA-approved generic drugs, and CMS publishes state-level drug utilization data that can be used to check what a state program has actually reimbursed for a given drug Medicaid state drug utilization data. That is the correct primary source for verifying Minnesota-specific trazodone coverage, prior authorization rules, and managed care organization formulary placement. This article does not have a Minnesota Department of Human Services policy document or MCO formulary in its source material, so specific claims about prior authorization criteria, copay tiers by MCO (Blue Plus, HealthPartners, Hennepin Health, UCare), or income-based copay brackets for MinnesotaCare cannot be stated as fact here. If a prescriber or patient needs that information, it should come from the Minnesota Department of Human Services Medical Assistance formulary or the specific MCO's published drug list, checked on the date of the prescription.

What can be said generally: because trazodone is off-label for insomnia (its only FDA-approved indication is major depressive disorder), payers are more likely to apply utilization controls, such as prior authorization or step therapy, to insomnia prescriptions than to prescriptions written for depression. Clinical guidelines for chronic insomnia in adults generally recommend cognitive behavioral therapy for insomnia (CBT-I) as a first-line approach before long-term pharmacotherapy, which is consistent with payers asking prescribers to document that behavioral options were considered before approving ongoing off-label drug therapy. Confirm current CBT-I documentation requirements with the specific plan, since this varies and changes.

Commercial insurance and Medicare Part D

Commercial insurers and Medicare Part D plans generally place long-generic, low-cost drugs like trazodone on their lowest cost-sharing tier because there is little financial reason not to. Under the Inflation Reduction Act, Medicare Part D enrollees have had an annual out-of-pocket prescription drug cap in effect since 2025, according to federal policy summaries. A drug priced in the low tens of dollars per month, like trazodone typically is, is very unlikely on its own to push a Medicare beneficiary anywhere near that annual cap, but the exact cap amount and any annual adjustments should be checked against the current CMS fact sheet rather than assumed to be static.

For any specific Minnesota insurer (HealthPartners, Blue Cross Blue Shield of Minnesota, Medica, UCare), the reliable way to confirm tier placement and whether prior authorization applies for the insomnia indication is the insurer's own current formulary lookup tool, not a general statement on this page. Formularies change at least annually and sometimes more often.

Compounded trazodone

Compounding of trazodone is legally permitted under the same federal framework that governs all compounded drugs. The FDA distinguishes 503A pharmacies, which compound patient-specific prescriptions, from 503B outsourcing facilities, which can produce larger batches without individual prescriptions FDA compounding Q&A. Because commercially manufactured trazodone tablets already cover the common strengths used clinically (roughly 50 mg to 150 mg, with a 300 mg strength also available), compounding is typically reserved for situations where a standard tablet does not meet a specific clinical need, for example a liquid formulation for a patient who cannot swallow tablets, a dose strength that falls between manufactured options, or an excipient-free formulation for a patient with a dye or filler sensitivity.

The FDA is explicit that compounded drugs, including compounded trazodone, are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or manufacturing quality the way an approved generic tablet has FDA compounding laws and policies. Compounded formulations are also generally priced higher than a standard manufactured generic tablet and are less likely to be covered by insurance unless medical necessity is documented and pre-approved. This article does not have Minnesota-specific compounding pharmacy pricing to report, and any dollar figure for compounded trazodone in Minnesota should be obtained directly from a licensed 503A pharmacy.

Telehealth prescribing

Because trazodone is not a federally controlled substance, it generally faces fewer telehealth-specific prescribing restrictions than controlled sleep medications such as zolpidem or benzodiazepines, which are subject to additional DEA rules around remote prescribing. State medical board rules on telehealth evaluation requirements do change over time and by state, so the specific current Minnesota Board of Medical Practice telehealth prescribing requirements should be confirmed directly with the board rather than assumed from a general federal telehealth resource. The cost of a telehealth visit itself (the consultation fee or insurance copay) is a separate line item from the medication cost and varies by platform and insurance plan; this article does not have Minnesota-specific telehealth visit pricing to report.

Clinical factors that change the real cost of therapy

A few clinical realities affect total cost independent of pharmacy shopping:

• Dose matters. Trazodone for insomnia is typically used at lower doses than trazodone for depression, where FDA labeling describes a substantially higher daily dose range in divided doses. A higher total daily dose means more tablets per month, which increases cost roughly in proportion to tablet count unless a higher-strength tablet is used instead.
• Drug interactions can affect dosing, not unit price. Trazodone is metabolized primarily through CYP3A4, and strong CYP3A4 inhibitors can raise trazodone blood levels, which may lead a prescriber to reduce the dose. The FDA label also warns against combining trazodone with MAOIs and urges caution with other serotonergic drugs because of serotonin syndrome risk. These are dosing and safety considerations for a prescriber to manage, not something a patient should adjust based on cost.
• Monitoring adds cost in some patients. Older adults or patients on multiple medications may need baseline or periodic monitoring (for example, checking for orthostatic hypotension), which adds visit or lab costs beyond the medication itself; whether this is needed is an individualized clinical decision.

None of this changes the per-tablet retail price, but it changes the total monthly and annual cost of therapy, which is often the number a patient actually cares about.

Evidence boundary: what is established, plausible, and unverified

Established: Trazodone is FDA-approved for major depressive disorder, is not a scheduled controlled substance, has been off-patent for decades with multiple generic manufacturers, and belongs to a drug class (long-generic oral tablet) that is reliably low-cost relative to brand-name alternatives. Federal frameworks for Medicaid drug coverage, 503A/503B compounding, and Medicare Part D's out-of-pocket cap are documented in CMS, FDA, and Medicaid.gov sources.

Plausible but not confirmed in this article's sources: Specific Minnesota cash-price averages, specific Minnesota Medicaid managed care copay amounts, specific prior authorization criteria language, and specific telehealth visit pricing in Minnesota. These are the kind of facts that are true somewhere and change often, and they require a live source check rather than a citation to a 2026 static article.

Not established: Any claim that trazodone reliably costs a specific dollar amount at Minnesota pharmacies "in 2026" without a dated, locatable source. A precise number stated with confidence but without a verifiable state-specific source is a bigger risk to a reader than an honest range with instructions on how to check it locally.

Verification checklist: stable facts vs. facts that expire

Use this checklist to identify which trazodone information remains reliable for your reference and which details warrant verification before making decisions about prescriptions or insurance coverage.

Stable, federal or clinical facts (safe to treat as durable, but still confirm the date on the source page):

• FDA-approved indication: major depressive disorder (1981 approval), verify via the FDA drug approval database.
• DEA controlled substance status: trazodone is not scheduled.
• Off-patent status: multiple generic manufacturers have been available for decades.
• Compounding framework: 503A (patient-specific) vs. 503B (outsourcing facility) distinction, per FDA.
• Medicare Part D annual out-of-pocket cap exists under the Inflation Reduction Act (confirm the current dollar amount on the CMS page, since it can be indexed).
• Major drug interaction classes: CYP3A4 inhibitors, MAOIs, other serotonergic agents (from FDA labeling).

Date-sensitive facts that must be re-verified before acting (do not rely on any number printed in an article without checking the date):

• Cash price at a specific Minnesota pharmacy or chain today.
• GoodRx/SingleCare/RxSaver quoted price today.
• A specific Minnesota Medicaid MCO's formulary tier and copay for trazodone.
• Whether prior authorization is currently required for the insomnia indication under a specific plan.
• MinnesotaCare or Medical Assistance income eligibility thresholds and copay brackets.
• A specific telehealth platform's visit fee in Minnesota.
• Compounding pharmacy pricing for a custom trazodone formulation.

How to verify each date-sensitive item: call the pharmacy directly for cash price, log into the specific insurer's member portal for formulary and copay information, check the Minnesota Department of Human Services Medical Assistance site for Medicaid rules, and ask the compounding pharmacy directly for a quote tied to the specific formulation ordered.

When to seek urgent care instead of price-shopping

Trazodone carries FDA warnings relevant to safety, not just cost. Seek urgent medical attention for symptoms of serotonin syndrome (agitation, rapid heart rate, high fever, muscle rigidity) if trazodone is combined with other serotonergic medications, for signs of an allergic reaction, for a painful or prolonged erection (priapism, a recognized rare adverse effect of trazodone), or for fainting or significant dizziness suggestive of orthostatic hypotension, especially in older adults. None of these situations should be managed by adjusting the prescription to save money; they require contacting the prescriber or emergency services.

Common questions

Does trazodone require prior authorization in Minnesota? This varies by payer and by indication (depression versus off-label insomnia use) and is not reliably summarized by a general statement. Check the specific plan's current formulary.

Is compounded trazodone the same as FDA-approved trazodone? No. Compounded trazodone is prepared by a licensed pharmacy for an individual patient and has not been evaluated by the FDA for safety, effectiveness, or manufacturing quality in the way an approved generic tablet has been. It is typically used only when a standard manufactured tablet does not meet a specific clinical need.

Can a Minnesota telehealth visit result in a trazodone prescription? Because trazodone is not a controlled substance, telehealth prescribing is generally more accessible for it than for controlled sleep medications, but current state medical board requirements for the evaluation itself should be confirmed directly rather than assumed.

Why is trazodone so much cheaper than newer sleep medications? Trazodone has been off-patent for decades with multiple generic manufacturers competing on price, while newer agents like suvorexant and lemborexant remain under patent protection as branded products, which keeps their prices substantially higher.

References

1. FDA. Approved Drug Products: Trazodone Hydrochloride, NDA 018207. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018207
2. FDA. Approved Drug Products: Suvorexant (Belsomra), NDA 212028. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212028
3. FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
4. FDA. Compounding Laws and Policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
5. Medicaid.gov. State Drug Utilization Data. https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html

Note for editorial review: the PubMed identifiers cited in the prior version of this page (for insomnia guidelines, trazodone efficacy reviews, STAR*D, telehealth cost comparisons, and generic pricing economics) could not be verified against the primary literature discovery process for this rewrite and have been removed rather than carried forward as unverified citations. If specific peer-reviewed support is needed for the clinical statements above (insomnia treatment guidelines, trazodone dosing evidence, CYP3A4 interaction data), those should be re-sourced and re-cited during medical review.